Clinical trials
Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials
Below are recruiting relapsed or refractory multiple myeloma (rrmm) clinical trials, each written for real people, not researchers. We’re tracking 1,262 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06378190RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Barcelona, BarcelonaAges 18–80 - NCT06389968Recruiting
Light therapy for vision after optic neuritis in MS
This study tests whether light stimulation can help improve vision after optic neuritis in people with multiple sclerosis. It may offer a way to support eye recovery without medication.
Munich, BavariaAges 18–60 - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+ - NCT06567197Recruiting
MS treatment with stem cell transplant in the Netherlands
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
AmsterdamAges 18–65 - NCT06569550Recruiting
Fatigue treatment study for multiple sclerosis
This trial tests a brain stimulation therapy designed to reduce fatigue in people with multiple sclerosis. If you experience moderate to severe fatigue and have a stable medication routine, this study might help determine if a non-invasive treatment can improve your energy levels.
Hvidovre, Capital RegionAges 18–65 - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT06611280Recruiting
Deuterium imaging study for people with multiple sclerosis
This study uses a special MRI technique to look at how brain cells use energy in people with relapsing-remitting MS. It may help doctors better understand MS and guide future treatments.
Aarhus CAges 18–60 - NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06644183RecruitingPhase 1/Phase 2
Triple therapy for relapsed CLL after prior treatments
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06663111Recruiting
Rituximab and Ocrelizumab levels in Multiple Sclerosis
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
Bergen, VestlandAges 18–60 - NCT06641271Enrolling by invitation
Vagus nerve stimulation with hand exercises for MS
This study tests if vagus nerve stimulation (a mild electrical pulse on the ear) combined with hand exercises can help repair the protective coating of your nerves and improve hand function in multiple sclerosis.
Aurora, ColoradoAges 18–70 - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06715436Recruiting
Ketogenic diet for multiple sclerosis
This study tests whether a ketogenic diet can help people with multiple sclerosis. You would follow a special high-fat, low-carb diet for a period, and the researchers will check its effects on your symptoms and overall health.
PaviaAges 18–60 - NCT06735248RecruitingPhase 2
Study testing mRNA vaccine for multiple sclerosis relapse prevention
This study tests whether an mRNA vaccine (mRNA-1195) can help prevent relapses in people with early relapsing multiple sclerosis (MS). It compares the vaccine to a placebo (a shot with no active ingredient) to see if it is safe and effective.
Boston, MassachusettsAges 18–55 - NCT06751134RecruitingPhase 1
Engineered immune cells for relapsed neuroblastoma in children
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
Nanjing, JiangsuAges 1–12 - NCT06810778RecruitingPhase 1/Phase 2
Duvelisib plus venetoclax for relapsed PTCL
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06864936Recruiting
Eye scan study for ublituximab in multiple sclerosis
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
Baltimore, MarylandAges 18–65 - NCT06919900Recruiting
Learning fall-resistant skills in multiple sclerosis
This trial tests if practicing slips and trips can help people with multiple sclerosis learn to prevent falls. You will be exposed to controlled slips and trips to improve your balance and walking safety.
Atlanta, GeorgiaAges 45–89 - NCT06947083RecruitingPhase 2
Elranatamab after cilta-cel for high-risk multiple myeloma
This trial tests a new drug, elranatamab, for people with multiple myeloma who recently received a CAR-T cell therapy (cilta-cel) but still have high-risk features. The goal is to see if elranatamab can help keep the cancer from coming back.
Tampa, FloridaAges 18 years+ - NCT06956326RecruitingPhase 2
Early rehab for multiple sclerosis relapse recovery
This trial tests whether early and specialized rehabilitation can help people with multiple sclerosis recover better after a motor relapse. It is for people who are already staying at a Danish MS Hospital for rehab.
HaslevAges 18 years+ - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma (rrmm)?
- Yes. Clin2 currently lists 1,262 recruiting relapsed or refractory multiple myeloma (rrmm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma (rrmm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma (rrmm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.